New England Southern A Self-Regulating Gene Therapy Vector for Treating Rett Syndrome
JSHS · 2025
Overview
Rett syndrome is a devastating neurodevelopmental disorder caused by loss -of-function mutations in the MeCP2 gene. Gene therapy represents one of the most promising strategies for treating or potentially curing this genetic disease. However, a key challenge in developing an effective gene replacement therapy for Rett syndrome is achieving sufficient MeCP2 express ion in affected cells without risking harmful overexpression. The aim of my study is to engineer a gene self-regulation system that maintains proper MeCP2 expression levels necessary for therapeutic benefit, while avoiding the detrimental effects associate d with MeCP2 overexpression. Building on my previous research presented at JSHS, I introduce a novel gene self -regulation system, “TREAD-Dimmer”, which leverages mechanisms of termination readthrough of the stop codon UGA and Cre -mediated recombination. In the TREAD-Dimmer system, high expression of the target gene triggers increased readthrough of a stop codon -containing sequence, leading to the translation of Cre recombinase fused downstream of the target gene. This results in Cre-mediated DNA recombination and self-deletion of the target gene, effectively downregulating its expression. Through cell culture experiments, I validated that TREAD -Dimmer can be applied to self - regulating gene therapy vectors, preventing overexpression of both green fluorescent protein and human MeCP2. Our ongoing collaborative efforts seek to further translate the TREAD -Dimmer system and its associated MeCP2 gene therapy vector into clinical applications. In conclusion, TREAD-Dimmer offers a promising solution to prevent overexpression in gene therapy, including MeCP2 gene replacement therapy for Rett syndrome, potentially improving therapeutic outcomes and minimizing risks associated with gene therapy treatments.
Competition history
- JSHS 2025
Resources
Related projects
ISEF · 2014
Investigating MeCP2 Regulation of L1CAM Gene Expression in Neural Stem Cells Derived from a Patient with Rett Syndrome
JSHS · 2024
New England Southern Engineering a Termination Readthrough-Based Gene Switch Enables Controllable CRISPR Gene Editing
ISEF · 2016
“Let There Be Light!” rAAV Mediated Delivery of shRNA in a Canine Model of Autosomal-dominant Retinitis pigmentosa
CWSF · 2026
Utilizing gene-editing and stem cell therapy to create a novel treatment plan for Tay-Sachs disease
CYSF · 2026
Evaluating Gene Therapy as a Treatment for ABCA3-Related Congenital Surfactant Deficiency
ISEF · 2017
A Path to Improving Gene Therapies for Liver-Related Diseases and Cancers through Selectable CRISPR-Cas9 Vectors
ISEF · 2025
Structure-Guided Engineering of Ancestrally Derived AAV Capsids: Enhancing Precision Gene Therapy Through the Rational De-Targeting of Hepatic Tropism
ISEF · 2018
Assessing the Impacts of CRISPR Editing on Protein Expression; Utilizing dCas9 as a Potential Roadblock to DNA Transcription
Closest projects by meaning, across every fair and year in the corpus.